Zheng Congying, Mao Chengliang, Tang Kai, Ceng Shaojian, Shu Hang
Department of Neurosurgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Arch Med Sci. 2020 Mar 9;20(3):726-735. doi: 10.5114/aoms.2020.93536. eCollection 2024.
microRNAs (miRs) have been reported as blood-based noninvasive indicators for the diagnosis of various diseases. However, the utility of whole blood-based miRs in the diagnosis of intracranial aneurysm (IA) is still not clear. The present study aimed to examine miR expression profiling in the peripheral whole blood of IA patients and healthy controls.
Seventy-three IA patients, including 34 unruptured and 39 ruptured, and 28 healthy subjects, were recruited for diagnostic analysis. microRNA (miR) expression profiling in whole blood from healthy controls and IA patients was evaluated using miRNA microarray assay. RT-qPCR was used to evaluate miR expression. Receiver operating characteristics (ROC) curves and the area under the ROC curves (AUC) were used to calculate the diagnostic power of miRs in whole blood of IA.
We observed significantly higher miR-21 and miR-92 expression levels in aneurysmal tissues and whole blood of IA patients as compared to healthy subjects. miR-21 expression level was significantly positively correlated with miR-92 in IA tissues and whole blood of IA patients. ROC analysis revealed that miR-21 (AUC = 0.843, sensitivity = 0.849, specificity = 0.750) and miR-92 (AUC = 0.892, sensitivity = 0.945, specificity = 0.786) were promising in diagnosis of IA with high detectability. Intriguingly, miR-21 combined with miR-92 markedly improved the diagnostic power of IA (AUC = 0.920, sensitivity = 1.000, specificity = 0.786).
miR-21 combined with miR-92 could be considered as a potential biomarker for IA screening.
微小RNA(miR)已被报道为用于各种疾病诊断的基于血液的非侵入性指标。然而,基于全血的miR在颅内动脉瘤(IA)诊断中的效用仍不明确。本研究旨在检测IA患者和健康对照者外周全血中的miR表达谱。
招募73例IA患者(包括34例未破裂和39例破裂患者)及28例健康受试者进行诊断分析。使用miRNA微阵列分析评估健康对照者和IA患者全血中的微小RNA(miR)表达谱。采用逆转录定量聚合酶链反应(RT-qPCR)评估miR表达。采用受试者工作特征(ROC)曲线及ROC曲线下面积(AUC)计算miR在IA全血中的诊断效能。
我们观察到,与健康受试者相比,IA患者的动脉瘤组织和全血中miR-21和miR-92的表达水平显著更高。在IA患者的IA组织和全血中,miR-21表达水平与miR-92显著正相关。ROC分析显示,miR-21(AUC = 0.843,灵敏度 = 0.849,特异度 = 0.750)和miR-92(AUC = 0.892,灵敏度 = 0.945,特异度 = 0.786)在IA诊断中具有较高的检测能力。有趣的是,miR-21与miR-92联合使用显著提高了IA的诊断效能(AUC = 0.920,灵敏度 = 1.000,特异度 = 0.786)。
miR-21与miR-92联合可被视为IA筛查的潜在生物标志物。